Dynamic Technology Lab Private Ltd Has $1.24 Million Holdings in Medpace Holdings, Inc. $MEDP

Key Points

• Dynamic Technology Lab Private Ltd increased its stake in Medpace Holdings, Inc. by 397.0%, holding a total of 4,080 shares valued at approximately $1.24 million.
• Several institutional investors, including Mawer Investment Management Ltd. and Jacobs Levy Equity Management Inc., have significantly boosted their holdings in Medpace, contributing to 77.98% of the company's stock being owned by institutional investors and hedge funds.
• Medpace reported a quarterly revenue of $603.31 million, exceeding estimates, with earnings per share at $3.10, up from $2.75 in the same quarter last year.

Dynamic Technology Lab Private Ltd boosted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 397.0% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,080 shares of the company's stock after purchasing an additional 3,259 shares during the quarter. Dynamic Technology Lab Private Ltd's holdings in Medpace were worth $1,243,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of MEDP. Mawer Investment Management Ltd. acquired a new position in Medpace during the first quarter worth about $212,131,000. Vulcan Value Partners LLC boosted its holdings in Medpace by 221.6% in the first quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company's stock valued at $99,159,000 after acquiring an additional 224,578 shares during the last quarter. Spyglass Capital Management LLC boosted its holdings in Medpace by 85.1% in the fourth quarter. Spyglass Capital Management LLC now owns 262,660 shares of the company's stock valued at $87,264,000 after acquiring an additional 120,778 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in Medpace by 675.8% in the first quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company's stock valued at $37,009,000 after acquiring an additional 105,807 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in Medpace by 9.4% in the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock valued at $361,596,000 after acquiring an additional 102,015 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Insider Buying and Selling

In other Medpace news, Director Cornelius P. Mccarthy III sold 1,662 shares of the firm's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $465.04, for a total value of $772,896.48. Following the completion of the transaction, the director owned 10,197 shares in the company, valued at $4,742,012.88. This trade represents a 14.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kevin M. Brady sold 12,000 shares of the firm's stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the completion of the transaction, the chief financial officer owned 6,000 shares of the company's stock, valued at approximately $2,725,380. This represents a 66.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 161,266 shares of company stock worth $74,111,427 in the last quarter. 20.30% of the stock is currently owned by company insiders.

Medpace Stock Performance

Shares of MEDP opened at $486.98 on Monday. The business has a 50-day moving average of $412.68 and a 200 day moving average of $344.18. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $501.30. The firm has a market cap of $13.68 billion, a P/E ratio of 36.21, a price-to-earnings-growth ratio of 3.06 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company had revenue of $603.31 million during the quarter, compared to analyst estimates of $537.70 million. During the same quarter last year, the firm posted $2.75 EPS. The firm's revenue for the quarter was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of research analyst reports. William Blair restated a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. Robert W. Baird raised their target price on Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Rothschild Redb lowered Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, September 3rd. Truist Financial raised their target price on Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. Finally, UBS Group lowered Medpace from a "neutral" rating to a "sell" rating and raised their target price for the company from $300.00 to $305.00 in a research report on Tuesday, July 29th. Two equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Reduce" and a consensus price target of $412.73.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.